Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459282 | 1.00 | CHRNA7 (0.53) | CHRNA7CYP1A2CYP2D6ALDH1A1CHRM2 | |
| SCHEMBL3842064 | 0.94 | CHRNA7 (0.47) | CHRNA7CYP1A2CYP2D6CHRM2CHRM1 | |
| SCHEMBL3839401 | 0.94 | CHRNA7 (0.47) | CHRNA7CYP1A2CYP2D6CHRM2CHRM1 | |
| SCHEMBL3839223 | 0.91 | CHRNA7 (0.53) | CHRNA7CYP1A2CYP2D6ALDH1A1CHRM2 | |
| SCHEMBL3839228 | 0.91 | CHRNA7 (0.53) | CHRNA7CYP1A2CYP2D6ALDH1A1CHRM2 | |
| SCHEMBL1460490 | 0.88 | CHRNA7 (0.53) | CHRNA7CHRM2CHRM1TLR7 | |
| SCHEMBL1460488 | 0.88 | CHRNA7 (0.53) | CHRNA7CHRM2CHRM1TLR7 | |
| SCHEMBL1146018 | 0.87 | CHRNA7 (0.40) | CHRNA7CHRM2CHRM1 | |
| SCHEMBL1146287 | 0.87 | CHRNA7 (0.40) | CHRNA7CHRM2CHRM1 | |
| SCHEMBL1146153 | 0.87 | CHRNA7 (0.40) | CHRNA7CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480228-B1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2016-11-16 | — | — | EP | claimed |
| US-8236803-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | claimed |
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-2945633-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20090054446-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2009-02-26 | — | — | US | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| EP-1809285-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048294-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| EP-1537104-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022556-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | NOVARTIS AG (CH) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885CYP1A2 934/4885CYP2D6 1391/4885 |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | CHRNA7 1/4885CYP1A2 274/4885CYP2D6 613/4885 |
| US-20090054446-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CHRNA7 1/4885CYP1A2 274/4885CYP2D6 613/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3801/4885CYP2D6 4172/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885CYP1A2 2465/4885CYP2D6 3919/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3801/4885CYP2D6 4172/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CYP1A2 3895/4885CYP2D6 4259/4885 |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CYP1A2 2253/4885CYP2D6 1816/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885CYP1A2 3722/4885CYP2D6 4137/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CYP1A2 3895/4885CYP2D6 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.